Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Olga S. Pokrovskaya"'
Autor:
Olga S. Pokrovskaya, M V Solovev, N P Soboleva, Larisa A. Kuzmina, E S Urnova, I G Rekhtina, Larisa P. Mendeleeva, Maya Firsova, V N Dvirnyk, Valeriy G. Savchenko, G A Klyasova
Publikováno v:
Терапевтический архив, Vol 92, Iss 7, Pp 70-76 (2020)
To assess the safety and efficacy of autologous haematopoietic stem cell transplantation (auto-HSCT) in multiple myeloma (MM) patients with dialysis-dependent renal failure.During a period from May 2010 to December 2016 fourteen MM patients with dial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::691c396014c9c52c16b53bec2c00b4f6
https://doi.org/10.26442/00403660.2020.07.000777
https://doi.org/10.26442/00403660.2020.07.000777
Autor:
AYu Zaritskii, ES Urnova, Larisa Girshova, Olga S. Pokrovskaya, Larisa P. Mendeleeva, MV Nareiko, YuA Alekseeva, Dmitry Motorin, Alexey Petrov, DV Babenetskaya
Publikováno v:
Clinical oncohematology. 10:372-380
Background. The development of radical therapy for multiple myeloma (MM) is still a pressing problem. This progressive disease requires repeated courses of therapy using drugs without cross-resistance. The prognosis of “double refractory” MM whic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::148cad4390bcccc226301b200e04c125
https://doi.org/10.21320/2500-2139-2017-10-3-372-380
https://doi.org/10.21320/2500-2139-2017-10-3-372-380
Autor:
M V Nareyko, Olga S. Pokrovskaya, L P Mendeleeva, Eduard G. Gemdzhian, Larisa A. Kuzmina, M V Solovyev, V G Savchenko, Yu. O. Davydova, Irina V. Galtseva, Nikolay M. Kapranov, Maya Firsova
Publikováno v:
Терапевтический архив, Vol 89, Iss 7, Pp 25-31 (2017)
To determine the efficiency of maintenance therapy with bortezomib in patients with multiple myeloma (MM) who have achieved complete remission (CR) after autologous hematopoietic stem cell (auto-HSCT), depending on the presence of minimal residual di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::445db75c1bb66faf65965f036ac878be
https://pubmed.ncbi.nlm.nih.gov/28766537
https://pubmed.ncbi.nlm.nih.gov/28766537
Autor:
Ryzhko Vv, T V Abramova, L A Grebenyuk, M V Solovyev, V G Savchenko, Elena O. Gribanova, M V Nareyko, M A Rusinov, T N Obukhova, O M Votyakova, Sergei M. Kulikov, L P Mendeleeva, Olga S. Pokrovskaya
Publikováno v:
Терапевтический архив, Vol 89, Iss 7, Pp 32-38 (2017)
To determine the prevalence of amp1q21 and its relationship to the clinical manifestations of multiple myeloma (MM).In December 2009 to March 2016, a total 134 patients aged 30 to 81 years (median 57 years) underwent a pretreatment FISH-study of bone
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::016386425f99fcc3a5fe477e0207d6a7
https://pubmed.ncbi.nlm.nih.gov/28766538
https://pubmed.ncbi.nlm.nih.gov/28766538
Autor:
Olga S. Pokrovskaya, Larisa P. Mendeleeva, Valery G. Savchenko, Maiia V. Firsova, Eduard G. Gemdzhian, Irina G. Rekhtina, L S Biryukova, Maxim V. Solovev
Publikováno v:
Blood. 132:5765-5765
Introduction. Multiple myeloma (MM) in its early onset is complicated by myeloma nephropathy in 20-30% of patients, 10% of whom require haemodialysis. Early studies have shown that renal dysfunction has no adverse effect on melphalan pharmacokinetics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7df349f13c4c5faa41e4df4297fcf37a
https://doi.org/10.1182/blood-2018-99-115880
https://doi.org/10.1182/blood-2018-99-115880
Autor:
Elena O. Gribanova, Maria V. Nareyko, Olga S. Pokrovskaya, V. L. Surin, Olga Koroleva, Eleonora Boeva, Islam Nakastoev, Mihail Drokov, Anjelika Danilina, Maia Firsova, Valeri G. Savchenko, Ekaterina Y. Demidova, Larisa P. Mendeleeva, Madina Kanaeva, Larisa A. Kuzmina, Irina V. Galtseva, M V Solovev, Evdokia S. Urnova, Vyacheslav Rizhko, Aleksander Grachev, Elena N. Parovichnikova
Publikováno v:
ResearcherID
Introduction. Patients (pts) with oncopathology who have hyperexpression of c-MYC demonstrate low response to chemotherapy and poor prognosis. In our study we investigated the level of c-MYC gene expression in pts withmultiple myeloma (MM) and/or mon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fc97c2b409c07749e81afb16fee572e
https://doi.org/10.1182/blood.v126.23.5324.5324
https://doi.org/10.1182/blood.v126.23.5324.5324
Autor:
Larisa P. Mendeleeva, Eduard G. Gemdzhian, Anna N. Balandina, Larisa A. Kuzmina, Sergei A. Vasil'ev, Elena A. Seregina, Valeri G. Savchenko, Fazoil I. Ataullakhanov, Maiia V. Firsova, Ivan D. Tarandovsky, Olga S. Pokrovskaya, Evdokia S. Urnova, Mariya V. Nareiko, Marina A. Gracheva
Publikováno v:
ResearcherID
Background: Course of multiple myeloma (MM) is associated with hemostatic disorders that can lead to bleeding or thrombosis. According to previous studies the most risky period of time for thrombotic complication is the first year after diagnosis. Ai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ba2b6100f0f926906e557513153b769
https://doi.org/10.1182/blood.v126.23.5388.5388
https://doi.org/10.1182/blood.v126.23.5388.5388
Autor:
Eduard G. Gemdzhian, Olga S. Pokrovskaya, Sergei A. Vasil'ev, Mariya V. Nareiko, Evdokia S. Urnova, Ivan D. Tarandovsky, Valeri G. Savchenko, Maiia V. Firsova, Marina A. Gracheva, Larisa P. Mendeleeva
Publikováno v:
ResearcherID
Background: Patients (pts) with multiple myeloma (MM) have an increased risk of thrombosis. Previous studies have shown that 3.7–4.6% of pts undergoing peripheral blood stem cell (PBSC) mobilization developed thrombotic complications. Aims: The aim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fbc36b4b54bb6abbd6bb25a4d158fb2
https://doi.org/10.1182/blood.v124.21.1131.1131
https://doi.org/10.1182/blood.v124.21.1131.1131
Autor:
I B Kaplanskaya, Olga S. Pokrovskaya, Elena N. Parovichnikova, V G Savchenko, Sergei M. Kulikov, L P Mendeleeva
Publikováno v:
Blood. 112:3321-3321
BACKGROUND. Angiogenesis is a constant hallmark of multiple myeloma (MM) progression. It has also been reported that bone marrow angiogenesis is a predictive factor of poor survival in newly diagnosed myeloma. The aim of the current study was to inve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b73646883b4d3e65a7b3c6400d5927a
https://doi.org/10.1182/blood.v112.11.3321.3321
https://doi.org/10.1182/blood.v112.11.3321.3321
Autor:
Svetlana N. Menshakova, Elena Volodicheva, Larisa P. Mendeleeva, Valeri G. Savchenko, Lyudmila Anchukova, Vladimir V. Voytsekhovski, Svetlana M. Osyunikhina, Olga S. Pokrovskaya, Eduard G. Gemdzhian, Maxim V. Solovev
Publikováno v:
ResearcherID
Background: The greatest progress in treatment of lymphoproliferative malignancy multiple myeloma (MM) was achieved in the past decade. According to population studies, in the last decade 5-year overall survival (OS) rate in patients (pts) with MM in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f79d24bd5869c4f307b5b8bc00c7b826
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000368021801190&KeyUID=WOS:000368021801190
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000368021801190&KeyUID=WOS:000368021801190
